AIM ImmunoTech (AIM) vs Creative Medical Technology (CELZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AIM ImmunoTech is the larger company by market cap ($7.2 million vs $6.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | CELZ |
|---|---|---|
| Share price | $0.1796 | $0.8604 |
| Market cap | $7.17M | $6.53M |
| 1-day change | -1.75% | -2.45% |
| EPS (TTM) | $-2.98 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $6.25 |
| 52-week low | $0.17 | $0.62 |
| Distance from 52-week high | -93.57% | -86.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +2266.37% | +2224.50% |
| Average volume | 4.70M | 6.77M |
| Shares outstanding | 39.89M | 7.59M |
| Employees | 19 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Creative Medical Technology
CELZ stock →Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4 employees
AIM vs CELZ FAQ
Which is bigger, AIM ImmunoTech or Creative Medical Technology?
AIM ImmunoTech (AIM) is larger, with a market capitalization of $7.17M compared with $6.53M for Creative Medical Technology (CELZ).
Are AIM ImmunoTech and Creative Medical Technology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.